March 2, 2016 | Dave Weiss
By now, government price departments are well underway towards implementing the Final Average Manufacturer Price (AMP) Rule recently issued by the Center of Medicare and Medicaid Services (CMS). AMP is the average manufacturer price paid by retail community pharmacies (RCP). One of the key provisions of the sub-regulatory guidance is related to “5i” drugs (i.e., infused, injected, implanted, inhaled, or instilled drugs) that are drugs that are “not generally dispensed“ (NGD) in retail pharmacies but rather at infusion centers, specialty pharmacies, and so on. Even though 5i drugs are not sold into retail, they still require an AMP for other […]
Read More
Tags: 5i drugs, 867 data, AMP rule, retail community pharmacies
March 1, 2016 | Kevin Leininger
Today we announced an equity partnership with Accel-KKR (AKKR) that is very exciting both for IntegriChain and our customers. Both IntegriChain and AKKR share a singular vision to service underserved constituencies in the life sciences industry. Life sciences companies are facing a rapidly evolving marketplace driven by changes across the entire healthcare ecosystem from providers to payers and distribution platforms. Navigating this requires life sciences companies to completely rethink the way they advance and support the patient journey. The days of primary care physicians and retail pharmacies serving branded, pill-based prescription products shipped once per week from wholesalers across the […]
Read More
Tags: AKKR, equity partnership
February 25, 2016 | Miguel Guerreiro
Drexel University’s College of Computing & Informatics hosted its fourth Philly CODEFEST, a two-day coding competition to transform data into real-world solutions. IntegriChain was a huge part of the event by providing judges and mentors and by hosting a workshop to talk to the students about what technology companies are looking for in co-ops and employees. This is just another instance of our continued effort to promote Philadelphia-area technology, which is really starting to expand in the region. We would like to congratulate everyone who won a prize including team Good Civilianship, who won the Grand Prize, the Student Grand Prize, and […]
Read More
Tags: coding, hackathon, Philadelphia, software engineering
January 29, 2016 | Sunay Shah
Everywhere you look, data is being collected and stored in an electronic format. From electronic medical records to the Internet of things, data collection is omnipresent; however, trying to figure out how to extract the maximum value from all of the collected data is a continuous process. Most industries–including consumer marketing, finance, healthcare, and technology–are seeing a revolution in how they analyze data as the amount of data they have at their disposal continues to increase by orders of magnitude. So much so that overall, 90% of the world’s data has been collected in the past two years.* Focusing on […]
Read More
Tags: analytics, data science, healthcare channel data, visualization
December 16, 2015 | Dave Weiss
While we applaud the Health Resources and Services Administration (HRSA) for its efforts to create more transparency in the 340B program through its proposed guidance and program integrity initiative, a quick inspection of the 2015 audit results posted on the Office of Pharmacy Affairs (OPA) website is deeply concerning. As part of this report, HRSA audited 137 covered entities in 2015, which was a 30% increase above 2014. If the results are extrapolated to the universe of 30,000+ covered entities (and their associated contract pharmacies) then the level of potential abuse is far worse than even its harshest critics could […]
Read More
Tags: 340B, chargebacks
December 2, 2015 | Josh Halpern
You might have noticed that we recently announced the release of a new set of channel visualizations focused on the retail pharmacy. In an era when specialty pharmacy so dominates our industry’s headlines, you might be surprised to learn that a growing number of our customers are turning renewed attention and resources to the retail pharmacy channel. Manufacturers are examining retail pharmacy design and pharmacist engagement with a fresh eye, and some are finding attractive opportunities to improve the patient experience and maximize brand success. First a little history. Back in the 20th century, before the advent of script data, drug […]
Read More
Tags: big data, Retail Pharmacy, visualization
October 27, 2015 | Kevin Leininger
We have partnered with Amazon Web Services (AWS) and have big plans to leverage the fastest growing cloud platform on the planet. The rate of growth and innovation in AWS is truly astonishing. I have been in the software business for 25 years and never seen anything quite like it.
Read More
July 13, 2015 | Digesh Kapadia
This was my second year in a row that I attended the AWS Summit in NYC at Jacob Javits. The event coincided with the celebration of 80th birthday of his Holiness the 14th Dalai Lama at the same place, so in some aspect it was a blessed summit. Just like last year, keynote Dr. Werner Vogels, Amazon’s Chief Technology Officer (CTO), touched upon new services they are rolling out, from Elastic File Storage (EFS) to AWS Device Farm and developer tools including AWS CodeCommit, CodePipeline, CodeDeploy, and more. The pace of innovation that happens within Amazon goes to the core of empowerment […]
Read More
Tags: cloud, enterprise applications
July 9, 2015 | Dave Weiss
For those of us who monitor the 340B Drug Pricing Program, a fascinating report and industry debate erupted this week over the June 2015 US Government Accountability Office (GAO) Report to Congress entitled “Medicare Part B Drugs: Action Needed to Reduce Financial Incentives to Prescribe 340B Drugs at Participating Hospitals." Debate has broken out after the report showed that while charitable and unreimbursed care are in fact higher at 340B hospitals, especially at those with higher Disproportionate Share Hospital (DSH) adjustments, some notable facts and trends in the program have emerged.
Read More
Tags: 340B, drug pricing discount program, revenue leakage
June 15, 2015 | Dave Weiss
The 340B program has been on the minds of many pharmaceutical, healthcare, public policy, and legal stakeholders of late. Regardless of how the so-called “mega-rule” evolves, most drug manufacturers cannot completely monitor the use and potential abuse of inventories fully through covered entities and contract pharmacies to patients.
Read More
